These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9142432)

  • 21. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).
    Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study)
    Circ J; 2002 Feb; 66(2):149-57. PubMed ID: 11999639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effect of MCI-154, a cardiotonic agent, on ischemic contractile failure and myocardial acidosis of dog hearts: comparison with dobutamine, milrinone and pimobendan.
    Abe Y; Kitada Y; Narimatsu A
    J Pharmacol Exp Ther; 1992 Jun; 261(3):1087-95. PubMed ID: 1602375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
    Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
    Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan.
    Tsuda T; Izumi T; Kodama M; Hanawa H; Takahashi M; Suzuki M; Aizaki T; Uchiyama H; Kuwano H; Shibata A
    Jpn Heart J; 1992 Mar; 33(2):193-203. PubMed ID: 1593749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy of congestive heart failure: pimobendan, a new approach to inotropic stimulation. Proceedings of a satellite symposium to the Xth European Congress of Cardiology. Vienna, Austria, August 31, 1988.
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S1-64. PubMed ID: 2478785
    [No Abstract]   [Full Text] [Related]  

  • 28. Pimobendan has a potent venodilating action in patients with congestive heart failure.
    Matsumoto A; Momomura S; Yokoyama I; Aoyagi T; Sugiura S; Omata M
    Cardiovasc Drugs Ther; 1998 Dec; 12(6):595-7. PubMed ID: 10410829
    [No Abstract]   [Full Text] [Related]  

  • 29. Improvement of cardiac performance by pimobendan, a new cardiotonic drug, in the experimental failing dog heart.
    Satoh K; Satoh Y; Imagawa J; Taira N
    Jpn Heart J; 1993 Mar; 34(2):213-9. PubMed ID: 8315818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A; Gordon SG; Häggström J; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
    J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure.
    Hagemeijer F
    Eur Heart J; 1993 Apr; 14(4):551-66. PubMed ID: 8472722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of oral administration of pimobendan in cats with heart failure.
    Gordon SG; Saunders AB; Roland RM; Winter RL; Drourr L; Achen SE; Hariu CD; Fries RC; Boggess MM; Miller MW
    J Am Vet Med Assoc; 2012 Jul; 241(1):89-94. PubMed ID: 22720992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of pimobendan in the treatment of heart failure.
    Duncker DJ; van Dalen FJ; Hartog JM; Lamers JM; Rensen RJ; Saxena PR; Verdouw PD
    Arzneimittelforschung; 1986 Dec; 36(12):1740-4. PubMed ID: 3032212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.
    Nonaka M; Morimoto S; Murayama T; Kurebayashi N; Li L; Wang YY; Arioka M; Yoshihara T; Takahashi-Yanaga F; Sasaguri T
    Br J Pharmacol; 2015 May; 172(9):2369-82. PubMed ID: 25560565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure.
    Reina-Doreste Y; Stern JA; Keene BW; Tou SP; Atkins CE; DeFrancesco TC; Ames MK; Hodge TE; Meurs KM
    J Am Vet Med Assoc; 2014 Sep; 245(5):534-9. PubMed ID: 25148095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of nonglycosidic inotropic agents: indications, ethics, and limitations.
    Chatterjee K; De Marco T
    Med Clin North Am; 2003 Mar; 87(2):391-418. PubMed ID: 12693731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing.
    Hagemeijer F; Brand HJ; Roth W
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):302-10. PubMed ID: 2476606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure.
    Hamabe L; Kawamura K; Kim SM; Yoshiyuki R; Fukayama T; Shimizu M; Fukushima R; Tanaka R
    J Pharmacol Sci; 2014; 124(3):386-93. PubMed ID: 24599141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.